Agilent Microarray Manufacturing Achieves ISO 13485 Compliance
Agilent Technologies Inc. announced that its entire portfolio of DNA microarrays is now manufactured under ISO 13485 certification, an internationally recognized standard for quality management systems (QMS).
“Agilent has always emphasized quality in the manufacture of microarrays, and we’re very pleased to be adding the validation of an ISO 13485-registered QMS on top of our existing ISO 9001 standard,” said Robert Schueren, Agilent vice president and general manager, Genomics and Life Science Reagents.
Agilent analytical instrumentation systems and microarray systems produced at the company’s Santa Clara facilities have been manufactured under an ISO 9001:2008 certified QMS since April 2009.
Other news from the department politics & laws

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Wheelchair

The dark matter of the brain - Omnipresent and yet hardly explored: Electrical synapses
New biomarker links cancer progression to genome instability - High level of specific protein in tumors indicates prognosis
KUROS announces allowance of European Patent for synthetic biomaterials
Agilent Technologies and Agendia Sign Agreement on Molecular Cancer Diagnostics
Category:Lyases

Technetics - Freiburg im Breisgau, Germany
Biochrom appoints Sam Luke as the new Group Managing Director

Phase 1 BAFF CAR T clinical trial for patients with relapsed and refractory multiple myeloma underway at UH Seidman Cancer Center - Study is being done through an agreement between UH and start-up Luminary Therapeutics
Category:Sexual_conflict
